Cerus Corp. (NASDAQ: CERS) is a real company with real revenues, but no profits yet, and could be at a $50 million revenue run rate in 2010.
It is a pioneer in something called "pathogen inactivation" -- a technology that cleans blood, making blood banks almost completely indifferent to the health of donors. It's the perfect system in the age of AIDS, bird flu and other infectious disease. Cerus' INTERCEPT Blood System is currently sold in 18 countries, and a potential major catalyst is an expedited approval process in the United States.
The stock is trading around a buck -- down from nearly $8 about a year ago -- and it could be worth $10 in a couple of years.
Your best strategy for life-changing profits?
Buy the stock and wait. You may be waiting a while, but this is a solid company with a real product and profits, and stock appreciation should come in the next two years. Make that big-time appreciation.
Next: Biotech Stock #6
Last year, as the market sank, one group actually went up -- large-cap, cashflow positive biotech and genomics companies.
Reid Hoffman: LinkedIn will go public (at some point)
Retailers can't wait for Black Friday, open Thursday
Tiffany's serves up solid quarterly earnings
